SB
The startup develops biopsy technology that analyzes circulating free DNA (cfDNA) from patient samples to provide oncologists with actionable insights for cancer management. This approach enhances patient care by enabling more precise treatment decisions based on genetic information derived from non-invasive testing.
Updated 2 months ago
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops biopsy technology that analyzes circulating free DNA (cfDNA) from patient samples to provide oncologists with actionable insights for cancer management. This approach enhances patient care by enabling more precise treatment decisions based on genetic information derived from non-invasive testing.